Core Viewpoint - Yong'an Pharmaceutical (002365.SZ) reported a decline in both revenue and net profit for the first three quarters of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved an operating income of 577 million yuan, representing a year-on-year decrease of 6.72% [1] - The net profit attributable to shareholders of the listed company was 25.5 million yuan, down 58.78% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 5.18 million yuan, reflecting a significant decline of 86.17% year-on-year [1]

Core Viewpoint - Yong'an Pharmaceutical (002365.SZ) reported a decline in revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company achieved an operating income of 577 million yuan, representing a year-on-year decrease of 6.72% [1] - The net profit attributable to shareholders was 25.5 million yuan, down 58.78% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 5.18 million yuan, a decrease of 86.17% year-on-year [1] - Basic earnings per share were reported at 0.0881 yuan [1]

证券代码：002365 证券简称：永安药业 公告编号：2025-62 潜江永安药业股份有限公司 第七届董事会第十次临时会议决议公告 根据公司经营发展需要，同意聘任董世豪先生为公司副总经理，聘任彭波先 生、吴旭先生、黄宁军先生为公司高级管理人员，任期自本次董事会审议通过之 日起至第七届董事会任期届满之日止。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 潜江永安药业股份有限公司（以下简称"公司"）第七届董事会第十次临时 会议的会议通知于 2025 年 10 月 24 日以书面、电话、传真、电子邮件等形式送 达公司全体董事，会议于 2025 年 10 月 29 日在公司会议室以通讯方式召开，本 次会议应参与审议表决董事 7 人，实际参与审议表决董事 7 人。本次会议由董事 长陈勇先生主持，会议的召集和召开符合《公司法》及《公司章程》的规定。会 议以书面记名投票方式逐项表决，通过了如下决议： 一、审议通过《关于选举第七届董事会副董事长的议案》 表决结果：同意 7 票，反对 0 票，弃权 0 票。 根据《公司章程》相关规定，同意选举董事陈子笛先生为公司第七届董事会 ...

Group 1 - The core viewpoint of the article highlights that Yong'an Pharmaceutical reported a revenue of 210 million yuan in the third quarter, representing a year-on-year increase of 8.75% [1] - The net profit for the third quarter was 13.0005 million yuan, showing a year-on-year growth of 38.75% [1] Group 2 - For the first three quarters, the total revenue was 577 million yuan, which reflects a year-on-year decline of 6.72% [1] - The net profit for the first three quarters was 25.4963 million yuan, indicating a significant year-on-year decrease of 58.78% [1]

Financial Performance - The company's revenue for Q3 2025 was ¥209,771,612.84, representing an increase of 8.75% compared to the same period last year[5]. - Net profit attributable to shareholders for Q3 2025 was ¥13,000,535.84, a significant increase of 38.75% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥2,899,082.25, up 91.82% compared to the previous year[5]. - Total operating revenue for the current period was ¥577,148,711.33, a decrease of 6.7% from ¥618,715,718.75 in the previous period[24]. - Net profit for the current period was ¥16,342,120.79, down 72.2% from ¥58,799,695.42 in the previous period[25]. - The profit attributable to the parent company's shareholders was ¥25,496,259.56, a decrease of 58.8% compared to ¥61,855,243.42 in the previous period[25]. - Basic earnings per share for the current period was ¥0.0881, down from ¥0.2105 in the previous period[25]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,262,430,873.84, a decrease of 2.00% from the end of the previous year[5]. - Total assets decreased to ¥2,262,430,873.84 from ¥2,308,602,905.85, reflecting a decline of 2.0%[23]. - Total liabilities decreased to ¥247,199,813.94 from ¥266,545,677.53, a reduction of 7.3%[23]. - Total equity attributable to the parent company was ¥1,976,432,019.92, down from ¥1,993,780,889.08, a decrease of 0.9%[23]. Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥98,664,888.88, an increase of 5.76%[5]. - Operating cash flow for the current period is ¥98,664,888.88, an increase of 0.4% compared to ¥93,294,328.83 in the previous period[26]. - Total cash inflow from investment activities decreased to ¥779,294,652.40 from ¥938,272,584.94, a decline of approximately 16.9%[26]. - Net cash flow from investment activities is -¥110,081,416.72, improving from -¥145,855,877.36 in the previous period[26]. - Cash inflow from financing activities decreased to ¥15,000,000.00 from ¥20,600,000.00, a decline of 27.0%[27]. - Net cash flow from financing activities is -¥76,004,051.88, worsening from -¥54,723,270.65 in the previous period[27]. - The net increase in cash and cash equivalents for the current period is -¥85,570,105.23, compared to -¥101,078,767.21 in the previous period[27]. - The ending balance of cash and cash equivalents is ¥234,835,187.73, up from ¥193,149,436.01 in the previous period[27]. - Cash received from the sale of goods and services is ¥604,670,318.15, down 8.2% from ¥658,699,780.62[26]. - Total cash outflow from operating activities is ¥548,206,206.09, a decrease from ¥634,892,089.71, reflecting a reduction of approximately 13.6%[26]. - Cash received from tax refunds is ¥18,198,428.70, down from ¥21,847,313.41, a decline of about 16.1%[26]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 57,923[12]. - The largest shareholder, Chen Yong, holds 21.54% of the shares, amounting to 63,468,000 shares[12]. - The company repurchased 5,537,350 shares, representing 1.88% of the total shares, ranking fourth among all shareholders[13]. - The top ten shareholders include Huanggang Yong'an Pharmaceutical Co., Ltd. with a 2.82% stake, amounting to 8,313,532 shares[12]. - The company completed a share reduction plan where the controlling shareholder reduced their stake by 2,632,300 shares, accounting for 0.8933% of the total share capital[16]. Corporate Actions - The company approved the acquisition of 49.20% equity from minority shareholders of Hubei Ling'an Technology Co., Ltd. for a total of RMB 27 million[15]. - Following the acquisition, the company will hold 100% equity in Ling'an Technology, with no changes to the consolidated financial statement scope[15]. - The company plans to adjust its business scope and increase the board members from 6 to 7, adding one employee representative director and one vice chairman[14]. - The company will abolish the supervisory board, transferring its powers to the audit committee of the board[14]. - The company completed the necessary business registration changes and obtained a new business license on October 21, 2025[14]. Legal and Compliance - The company is actively monitoring the progress of a patent infringement lawsuit in the U.S. where it was previously cleared of any infringement claims[17]. Operational Challenges - The company experienced a 73.63% decrease in operating profit, attributed to a decline in sales volume and price of its main product, taurine[10]. - Sales expenses increased by 167.48% year-on-year, mainly due to increased promotion and advertising costs for the company's self-owned brand products[9]. - The company has reported a significant decrease in cash reserves, which may impact future operational liquidity[21].

Core Viewpoint - The company emphasizes the importance of safety in production as a fundamental principle for its development, especially in light of recent safety incidents in the industry [2]. Group 1 - The company is committed to high-quality development and will implement various measures to strengthen safety foundations and improve operational quality [2]. - The company aims to ensure sustainable and healthy growth in its operations [2].

Group 1 - The core viewpoint of the article is that Yong'an Pharmaceutical's subsidiary, Yong'an Kangjian Yijian, is progressing as planned in expanding its offline channel for self-branded products and is currently in discussions with mainstream chain channels [2] Group 2 - Yong'an Pharmaceutical is actively engaging in communication and negotiation with major retail chain partners to enhance its market presence [2] - The company is focused on a structured approach to advance its product distribution strategy [2]

Core Viewpoint - Yong'an Pharmaceutical reported that as of October 10, 2025, the number of shareholders reached 58,256 [2] Company Summary - Yong'an Pharmaceutical's shareholder count is projected to be 58,256 by October 10, 2025 [2]

Core Viewpoint - The management of Yong'an Pharmaceutical emphasizes the importance of fundamental performance as the core support for stock price, aiming to enhance profitability and intrinsic value as primary tasks [2] Group 1: Business Strategy - The company is focused on strengthening its competitive advantage in the taurine business through market expansion, research and development innovation, cost reduction, efficiency improvement, and management optimization [2] - Yong'an Pharmaceutical plans to diversify by expanding into surrounding products and downstream processing markets related to taurine, aiming to cultivate new growth points for performance [2] Group 2: Management Commitment - The management is committed to improving operational quality and will continue to implement various operational measures to enhance the company's performance [2]

Core Viewpoint - Yong'an Pharmaceutical (002365.SZ) is progressing as planned with its offline channel for self-owned brand products through its subsidiary Yong'an Kangjian Yijian, currently in discussions with mainstream chain channels [1] Group 1 - Yong'an Kangjian Yijian is advancing its offline channel strategy in an orderly manner [1] - The company is in the communication and negotiation phase with major chain channels [1]